Thiotepa-induced myelosuppression: Review of 670 bladder instillations

M. S. Soloway, K. S. Ford

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Intravesical chemotherapy is an integral part of the therapeutic strategy for patients with superficial bladder cancer. Despite the introduction of new agents thiotepa is used most owing to its low cost and moderate effectiveness. Myelosuppression is a side effect caused by absorption of the drug through the bladder mucosa. A review of 670 instillations of thiotepa in 72 patients at our medical center revealed a decrease in the white or platelet count below normal in 18 per cent of the patients (3.9 per cent of the instillations). In no case did this decrease lead to any problem other than a delay in therapy.

Original languageEnglish (US)
Pages (from-to)889-891
Number of pages3
JournalJournal of Urology
Issue number5
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Thiotepa-induced myelosuppression: Review of 670 bladder instillations'. Together they form a unique fingerprint.

Cite this